"Diketopiperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Piperazines with two keto oxygens.
| Descriptor ID |
D054659
|
| MeSH Number(s) |
D03.383.606.385
|
| Concept/Terms |
Diketopiperazines- Diketopiperazines
- Piperazinediones
- Diketopiperazine Compounds
- Diketopiperazine
|
Below are MeSH descriptors whose meaning is more general than "Diketopiperazines".
Below are MeSH descriptors whose meaning is more specific than "Diketopiperazines".
This graph shows the total number of publications written about "Diketopiperazines" by people in this website by year, and whether "Diketopiperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 0 | 3 | 3 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diketopiperazines" by people in Profiles.
-
Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. Adv Ther. 2026 Aug; 43(8):3535-3551.
-
Optimizing the patient journey: Insights from early implementation of long-acting cabotegravir and rilpivirine in four urban Ryan White-funded clinics in the United States. J Int AIDS Soc. 2026 Feb; 29(2):e70082.
-
Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic. J Antimicrob Chemother. 2025 11 04; 80(11):3092-3100.
-
"The Simplest Way to Go": An Exploration of Why Women Who Inject Drugs Chose Long-Acting Injectable Cabotegravir Instead of Daily Oral PrEP. AIDS Behav. 2025 Dec; 29(12):3970-3980.
-
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process. Lancet HIV. 2025 Sep; 12(9):e649-e659.
-
Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long-acting cabotegravir/rilpivirine among early adopters in three U.S. clinics. J Int AIDS Soc. 2024 Nov; 27(11):e26394.
-
Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed. J Acquir Immune Defic Syndr. 2024 07 01; 96(3):280-289.
-
Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 09 01; 37(11):1711-1714.
-
The requirement of Artemis in double-strand break repair depends on the type of DNA damage. DNA Cell Biol. 2008 Jan; 27(1):55-61.
-
Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage. DNA Cell Biol. 2005 Jun; 24(6):388-93.